Last updated: April 21, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Overall Status: Completed
Phase
3
Condition
Throat And Tonsil Infections
Meningitis
Meningococcal Infection
Treatment
N/AClinical Study ID
NCT02274285
J2I02 (EFC13640)
U1111-1143-9112
Ages 2-68 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Aged 2 months to 68 months inclusive (recommended 3 to 8 months for Groups A and B; 2months for Group C) on the day of inclusion
- Informed consent form signed by the parent(s) or other legal representative
- Able to attend all scheduled visits and to comply with all trial procedures.
Exclusion
Exclusion Criteria:
- Fever ≥ 37.5°C (axillary temperature) on the day of inclusion
- Any serious disease whether acute or chronic
- Past or current medical history of Guillain-Barre syndrome, acute thrombocytopenicpurpura or encephalopathy
- History of diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzaetype b infections
- History of a life threatening reaction to a vaccine containing the same substances ofthe study vaccine
- History of anaphylaxis to any of the study vaccine components
- Previous vaccination against diphtheria, tetanus, pertussis, poliomyelitis orHaemophilus influenzae type b infections with a trial vaccine or another vaccine
- Congenital or current acquired immunodeficiency, immunosuppressive therapy such aslong-term systemic corticosteroids therapy
- Participation in another clinical trial preceding the trial inclusion
- Planned participation in another clinical trial during the present trial period
- Blood or blood-derived products received in the past or current or plannedadministration during the trial (including immunoglobulins)
- Any vaccination with live vaccines within the past 27 days preceding the first trialvaccination
- Any vaccination with inactivated vaccines within the past 6 days preceding the firsttrial vaccination
- Clinical or known serological evidence of systemic illness including Hepatitis B,Hepatitis C and/or HIV infection
- Subject ineligible according to the Investigator's clinical judgment
- Identified as employee of the Investigator or study center, with direct involvement inthe proposed study or other studies under the direction of that investigator or studycenter, as well as family member (i.e., immediate, husband, wife and their children,adopted or natural) of the employees or the Investigator.
Study Design
Total Participants: 424
Study Start date:
October 01, 2014
Estimated Completion Date:
May 28, 2016
Study Description
Connect with a study center
Aichi,
JapanSite Not Available
Chiba,
JapanSite Not Available
Fukui,
JapanSite Not Available
Fukuoka,
JapanSite Not Available
Gunma,
JapanSite Not Available
Hokkaido,
JapanSite Not Available
Miyagi,
JapanSite Not Available
Nagano,
JapanSite Not Available
Osaka,
JapanSite Not Available
Shizuoka,
JapanSite Not Available
Tokyo,
JapanSite Not Available
Yamanashi,
JapanSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.